Newly FDA Approved Alzheimers Biomarkers Testing How to Implement Such Tests in Core Laboratory?

Course overview

The diagnostic paradigm for Alzheimer's disease (AD) has rapidly shifted in the last five years as fluid-based biomarker testing has emerged as a reliable, accurate, and accessible means to detect amyloid pathology when evaluating a patient for cognitive decline. This activity is designed to help pathologists and laboratory professionals gain an understanding of plasma testing for markers such as Abeta40/42, P-tau181, and P-tau217 which are rapidly appearing in the commercial space and how healthcare providers have begun incorporating these tests into routine neurology practice. This course will help participants to understand the advantages and limitations of these assays as well as their potential application when a physician is evaluating a patient for AD.